Can Revlimid be used to treat anemia in Myelodysplastic Syndromes?

Revlimid (lenalidomide) is a treatment option for anemia in certain patients with myelodysplastic syndromes (MDS). It is specifically approved for adults with low- or intermediate-1-risk MDS who have a specific chromosome abnormality called deletion 5q and need regular red blood cell transfusions. Not all MDS patients with anemia will benefit from Revlimid; it is targeted to this subgroup.

What the research says

Revlimid is FDA-approved for treating transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q abnormality, with or without additional cytogenetic changes ¹. This approval is based on clinical studies showing that lenalidomide can reduce or eliminate the need for transfusions in these patients. The drug is a thalidomide analogue and works by affecting the bone marrow to improve blood cell production ¹. For lower-risk MDS patients, treatment of anemia may include growth factors, lenalidomide, and transfusions ⁶. Lenalidomide is one of the few FDA-approved agents for MDS, along with azacitidine and decitabine ⁸. However, it is not indicated for all MDS patients; its use is limited to those with the specific 5q deletion and lower-risk disease ¹. Other treatments for anemia in lower-risk MDS include erythropoiesis-stimulating agents (ESAs) as first-line therapy, and for those who do not respond to or are ineligible for ESAs, a telomerase inhibitor called Rytelo (imetelstat) was recently approved ⁴⁷.

What to ask your doctor

• Do I have a deletion 5q abnormality in my MDS cells?
• What is my MDS risk category (low or intermediate-1)?
• How many red blood cell transfusions have I needed, and am I a candidate for Revlimid?
• What are the potential side effects of Revlimid, and how are they managed?
• Are there other treatment options for my anemia, such as ESAs or Rytelo, and how do they compare?